IXONOS PREPARES ARRANGING ITS FINANCING AND A DIRECTED

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
IXONOS PREPARES ARRANGING ITS FINANCING AND A DIRECTED SHARE ISSUE

Helsinki, Finland, 2015-11-30 19:00 CET (GLOBE NEWSWIRE) --

 IXONOS PLC           STOCK EXCHANGE RELEASE          30.11.2015 at 20:00

Not to be published or distributed in or into the United States, Canada, Australia, Hong Kong, South Africa or Japan.

IXONOS PREPARES ARRANGING IT’S FINANCING AND A DIRECTED SHARE ISSUE

Ixonos Plc (“Ixonos” or “Company”) is conducting negotiations on its financing arrangements (“Arrangement”) with its five financiers not related to its owners (“Financial Institutions”) and Tremoko Oy Ab (“Tremoko”). In the Arrangement, the Financial Institutions or some of them would, in addition to other reorganisation, grant partial waiver of the Company’s debts (“Composition”), with the total value of the waiver being estimated at approximately EUR 4 million. In connection with the Arrangement, the Company would arrange a directed share issue in derogation of the shareholders’ pre-emptive subscription right (“Directed Share Issue”) in which the Company’s Board of Directors would decide, on the basis of the authorisation of the Annual General Meeting 29 April 2015, on issuing new Company shares for subscription by one or more Financial Institutions for the subscription price of EUR 0.085 per share, altogether worth approximately EUR 0.65 million. In the Directed Share Issue, the Financial Institutions would be entitled to pay the subscription price of the Shares they subscribe for by setting off claims they have from the Company.

It would also be agreed in connection with the Arrangement that Ixonos’ financing based on borrowed capital with interest is reorganised between the Company, the Financial Institutions and the Company’s largest shareholder Tremoko. After the Arrangement and the planned subscription rights issue announced on 11 November 2015, the Company would have a total of approximately EUR 8.0–8.5 million in financing based on borrowed capital with interest, divided so that altogether approximately EUR 0.5–1.0 million is from the Financial Institutions and EUR 7.5–8.0 million from Tremoko, which may or may not include rights entitling to shares that are set out in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act (a loan or a convertible loan). On 30 September 2015, the Company had approximately EUR 18.9 million’s worth of financing based on borrowed capital with interest.

Carrying out the arrangement requires approval from the Financial Institutions. Tremoko has set as conditions for the said rearrangement of financing based on borrowed capital with interest that the Composition is executed, that the Directed Share Issue is arranged and that other terms of the Arrangement are agreed upon.

As a whole, the Composition and the Directed Share Issue would support the Company’s financial standing in a situation in which the Company predicts that the turnover of the whole of 2015 is EUR 16-18 million and assesses that the operating result weakens in comparison to the year 2014 and that the Company’s operative cash flow is negative. The planned Arrangement would substantially enhance Ixonos’ solvency ratio.

IXONOS PLC

Board of Directors

Further information:

Ixonos Plc

CEO Sami Paihonen, tel. 050 502 1111, sami.paihonen@ixonos.com

CFO Kristiina Simola, tel. 040 756 3132, kristiina.simola@ixonos.com

Distribution:

NASDAQ OMX Helsinki

Main media

DISCLAIMER

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, South Africa or Japan. These written materials do not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

The issue, exercise and/or sale of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published or offering circular distributed by the Company.

The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland and which has implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression an "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to exercise, purchase or subscribe the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.

This communication is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 114

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 91

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

Piper Sandler Welcomes John Kerins to Healthcare Team

Updated Category News Views 218

Piper Sandler Expands Healthcare Investment Banking Expertise Piper Sandler Companies (NYSE: PIPR), a prominent name in investment banking, is excited to announce a significant addition to their healthcare investment banking team with the hiring of John Kerins as a managing director. This strategic move reflects the firm’s commitment to strengthening its presence in the...

Continue Reading
Exploring North America's Last Mile Delivery Growth and Trends

Updated Category News Views 346

Exploring North America's Last Mile Delivery Growth and Trends The last mile delivery market in North America is poised for significant growth over the next few years. Experts estimate that this market could expand by USD 14.9 billion between 2025 and 2029. This impressive growth is being driven primarily by the increasing demand for business-to-consumer (B2C) e-commerce....

Continue Reading
Mastercard Marks 20 Years on NYSE with Digital Shift

Updated Category News Views 39

A Landmark Moment at the NYSE for Mastercard Ah, another day in the whirlwind of the stock universe, where birthdays are celebrated with the finesse of boardroom discussions. Mastercard (NYSE: MA) is taking a well-deserved spotlight as it cheers two decades since it hit the seal of the New York Stock Exchange. Back on May 26th, it wasn't just business as usual. Nope, they...

Continue Reading
Insights into the Expanding Network of China-Europe Freight Trains

Updated Category News Views 236

The Rise of China-Europe Freight Trains Recently, a significant milestone was reached when the 110,000th China-Europe freight train departed from Jiaozhou Station, fully loaded with various goods such as electronic displays and household appliances. This service has now transported goods worth over USD 450 billion, showcasing its crucial role in global trade. The Journey...

Continue Reading
Netflix Investors Encouraged to Report Losses Amid Investigation

Updated Category News Views 217

Investigation Focus on Netflix, Inc. (NASDAQ: NFLX) Recently, significant scrutiny has emerged surrounding Netflix, Inc. (NASDAQ: NFLX), as Edelson Lechtzin LLP, a prominent national law firm known for handling class action lawsuits, initiates an investigation into potential violations of federal securities laws. This inquiry seeks to determine whether Netflix and certain...

Continue Reading